Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 2. Identification of patients with lung cancer and breast cancer.

Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 2. Identification of patients with lung cancer and breast cancer. - eNose in lung cancer/SCENT study, part 2

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32897

Enrollment

300

Registered

2008-12-30

Start date

2009-01-22

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer or bronchial carcinoma/ breast cancer or mamma carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. all women (18-80 yr) suspected of having breast cancer, referred to the OPD specialised in the diagnostic work-up of breast abnormalities in our hospital (*mamma poli*) will be asked to participate (intention-to-diagnose). 2. all patients (18-80 yr) suspected of having lung cancer, referred to the pulmonary OPD in our hospital will be asked to participate (intention-to-diagnose).

Exclusion criteria

Exclusion criteria: Patients of whom it is not possible to make the diagnose lung cancer or breast cancer. eating (including chewing gum), drinking,brushing teeth, smoking

Design outcomes

Primary

Measure	Time frame
Sensitivity, specificity, positive and negative predictive value of the eNose combined with the statistical algorithm developed from the training-set in the SCENT study part 1.	—

Countries

Netherlands

Outcome results